Skip to content

Abstract 8496: Left Ventricular Aneurysm and Thromboembolic Risk in Hypertropic Cardiomyopathy Without Atrial Fibrillation

Nov 2026 · Circulation · 0 citations

Abstract

Background: Left ventricular (LV) apical aneurysms occur in a subset of patients with hypertrophic cardiomyopathy (HCM) and have been associated with ventricular arrhythmias and sudden cardiac death. However, the independent thromboembolic risk attributable to LV aneurysm in HCM, particularly in the absence of atrial fibrillation, remains poorly defined. We sought to evaluate the association between LV aneurysm and thromboembolic events, ventricular arrhythmias, and clinical outcomes in a large, real-world HCM cohort. Methods: Using the TriNetX federated electronic health record network, we identified adults ≥18 years with HCM and LV aneurysm (n=806) and HCM without LV aneurysm (n=64,195). Patients with atrial fibrillation or anticoagulant use were excluded. After 1:1 propensity score matching on demographics, comorbidities, medications, and labs, 801 patients per group were analyzed. The primary endpoint was thromboembolic events (defined as a composite of systemic embolism, stroke, and transient ischemic attack). Secondary endpoint included stroke, all-cause mortality, ventricular tachycardia/fibrillation (VT/VF), reduction in LV ejection fraction (LVEF <50%) at 5 years. Landmark analyses at 30 and 90 days were performed. Results: After matching, groups were well balanced (mean age 63.3±15.3 years, 55.0% female). At 5 years, the thromboembolic events were significantly higher with LV aneurysm (12.8% vs 9.1%; HR 1.57, 95% CI 1.16-2.12; p=0.003), driven by stroke (10.7% vs 6.2%; HR 1.91, 95% CI 1.35-2.71; p<0.001). VT/VF was more frequent in the aneurysm group (13.1% vs 8.7%; HR 1.65, 95% CI 1.22-2.24; p=0.001), as was progression to reduced LVEF (4.4% vs 2.2%; HR 2.17, 95% CI 1.23-3.84; p=0.006). Composite adverse endpoint occurred more frequently in the aneurysm group (29.6% vs 25.7%; HR 1.35, 95% CI 1.12-1.62; p=0.002). All-cause mortality did not differ significantly (8.2% vs 11.6%; HR 0.81, 95% CI 0.59-1.11; p=0.181). Landmark analyses at 30 and 90 days showed no early separation between groups. Conclusion: In HCM patients without atrial fibrillation, LV aneurysm is independently associated with a nearly 2-fold increased risk of stroke and significantly higher rates of thromboembolic events, VT/VF, and progression to reduced LVEF at 5 years. These findings suggest that LV aneurysm may warrant consideration as an independent indication for anticoagulation and enhanced arrhythmia surveillance in HCM, even in the absence of atrial fibrillation.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.